The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
An overview of FDA-approved new molecular entities: 1827–2013
Abstract
The pharmaceutical industry is undergoing fundamental change and its future is unclear. We performed a meta-analysis by cataloging FDA-approved legacy drugs and new molecular entities (NMEs). Objective information regarding scientific, medical and commercial activities was captured and provides insight into processes governing drug development. In this report, we review the rates of NME introduction through to the end of 2013. Recent trends show the emergence of a handful of companies that controls two-thirds of NMEs. We also report growth in the number of NMEs controlled by marketing organizations that have little or no internal drug discovery or development activities. This trend has increased dramatically since 2000 and could raise important questions about the future landscape and viability of drug discovery and development.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“By comparison, development of new classes of drugs for the treatment of hypertension has remained steady over the same time period18 (Fig. 1).”
From Resolving the neural circuits of anxiety (2015) · cites this paper as [18]
In the citing paper
“Since the 1950s, new molecular entities approved by the US Food and Drug Administration (FDA) with primary indications for anxiety have been limited to benzodiazepines and the atypical anxiolytics buspirone, meprobamate and hydroxyzine pamoate18.”
From Resolving the neural circuits of anxiety (2015) · cites this paper as [18]
Citations
Cites
Deconstructing the Drug Development Process: The New Face of Innovation
Kaitin, K. I. (2010) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2009.293 · Cited by 419
Pharmaceutical Innovation in the 21st Century: New Drug Approvals in the First Decade, 2000–2009
Kaitin, K. I., & DiMasi, J. (2010) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2010.286 · Cited by 332
Overview of the Hatch-Waxman Act and its impact on the drug development process.
Gj, M. (1999) · PubMed · Cited by 133
Aspirin: The Remarkable Story of a Wonder Drug
Jeffreys, D. (2004) · Cited by 83
Stelzer, W., Aiglesberger, M., Stelzer, D., & Stelzer, V. (2012) · Pain Medicine · doi:10.1111/pme.12014 · Cited by 71
COX-2 Inhibition: What We Learned—A Controversial Update on Safety Data
Katz, J. A. (2013) · Pain Medicine · doi:10.1111/pme.12252 · Cited by 38
Historical milestones and discoveries that shaped the toxicology sciences
Hayes, A., & Gilbert, S. G. (2009) · Proceedings of the Fourth International Symposium on Polarization Phenomena in Nuclear Reactions · doi:10.1007/978-3-7643-8336-7_1 · Cited by 27
Flagged first, then by citations
Research works printed but not linked: 1
- GlaxoSmithKline Press release, 2014
Cited by
Sorted by citations
Items 101–200 of 211
ADMET analysis of phyto-components of Syzygium cumini seeds and Allium cepa peels
Kadri, H. S., & Minocheherhomji, F. P. (2020) · Future Journal of Pharmaceutical Sciences · doi:10.1186/s43094-020-00136-9 · Cited by 13
Kinch, M. S., & Moore, R. (2016) · Cell chemical biology · doi:10.1016/j.chembiol.2016.05.013 · Cited by 14
Self-citationIzuegbuna, O. (2021) · Nutrition and Cancer · doi:10.1080/01635581.2021.1924209 · Cited by 12
CDEK: Clinical Drug Experience Knowledgebase
Griesenauer, R. H., Schillebeeckx, C., & Kinch, M. S. (2019) · Database · doi:10.1093/database/baz087 · Cited by 12
Self-citationSims, D. B., Monk, J., Garner, M. C., Hudson, A. C., Keller, J. E., Aguaiza, C., Lindley, K., Woldetsadik, D. A., & Buch, A. C. (2024) · International Journal of Environmental Science and Technology · doi:10.1007/s13762-024-05522-x · Cited by 11
Nano-drug delivery system of natural products for disease prevention and treatment
Gao, S., Zhou, J.-R., Yokomizo, K., & Fang, J. Q. (2025) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2025.2506830 · Cited by 12
Ozierański, P., Martinon, L., Jachiet, P.-A., & Mulinari, S. (2022) · International Journal of Health Policy and Management · doi:10.34172/ijhpm.2022.6575 · Cited by 13
Schreiter, S., Vafia, K., Barsacchi, R., Tsang, S. H., Bickle, M., Ader, M., Karl, M., Tanaka, E. M., & Almedawar, S. (2020) · Stem Cell Reports · doi:10.1016/j.stemcr.2020.10.013 · Cited by 11
Ferreira, P. M. P., de Sousa, L. Q., de Sousa, R. W. R., Rodrigues, D. D. J., Filho, E. D. S. M., Chaves, M. H., Júnior, G. M. V., Rizzo, M. D. S., Filgueiras, L. A., Mendes, A. N., et al. (2023) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2023.116406 · Cited by 10
Toward a pharmacy curriculum theory: spiral integration for pharmacy education
Rockich‐Winston, N. (2017) · International Journal of Medical Education · doi:10.5116/ijme.58a8.0381 · Cited by 10
Kinch, M. S., Kinch, G. A., & Griesenauer, R. H. (2018) · Drug Discovery Today · doi:10.1016/j.drudis.2018.09.006 · Cited by 10
Self-citationDisruptive innovation and R&D ownership structures
Guo, D., Huang, H., Jiang, K., & Xu, C. (2020) · Public Choice · doi:10.1007/s11127-020-00850-1 · Cited by 10
Tools shaping drug discovery and development
Cheung, E., Xia, Y., Caporini, M. A., & Gilmore, J. L. (2022) · Biophysics Reviews · doi:10.1063/5.0087583 · Cited by 9
Pharmacogenetic biomarkers for predicting drug response
Bank, P. C. D., Swen, J. J., & Guchelaar, H. (2014) · Expert Review of Molecular Diagnostics · doi:10.1586/14737159.2014.923759 · Cited by 9
An analysis of FDA-approved drugs for metabolic diseases
Kinch, M. S., Umlauf, S., & Plummer, M. S. (2015) · Drug Discovery Today · doi:10.1016/j.drudis.2015.02.002 · Cited by 9
Self-citationGreen, A. R., Haddad, P. M., & Aronson, J. K. (2018) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.13549 · Cited by 9
Academic–Industrial Collaboration: Toward the Consilience of Two Solitudes
Hanessian, S. (2015) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.5b00488 · Cited by 9
Advocating for Mutually Beneficial Access to Shelved Compounds
Pulley, J. M., Jerome, R. N., Shirey-Rice, J. K., Zaleski, N. M., Naylor, H. M., Pruijssers, A. J. P., Jackson, J. C., Bernard, G. R., & Holroyd, K. J. (2018) · Future Medicinal Chemistry · doi:10.4155/fmc-2018-0090 · Cited by 9
Natural Products for Treatment of Chronic Myeloid Leukemia
Khajapeer, K. V., & Rajasekaran, B. (2016) · InTech eBooks · doi:10.5772/66175 · Cited by 8
Molecular Docking in Halogen Bonding
Suárez-Castro, A., Valle-Sánchez, M., Cortés-Garcia, C. J., & Chacón-Garcı́a, L. (2018) · InTech eBooks · doi:10.5772/intechopen.72994 · Cited by 8
Research synergy and drug development: Bright stars in neighboring constellations
Keserci, S., Livingston, E., Wan, L., Pico, A. R., & Chacko, G. W. (2017) · Heliyon · doi:10.1016/j.heliyon.2017.e00442 · Cited by 8
Macak, D., Kanis, P., & Riesenberg, S. (2025) · Nature Communications · doi:10.1038/s41467-025-67243-0 · Cited by 7
Shah, P., Vaughan, G., & Ledley, F. D. (2023) · PLoS ONE · doi:10.1371/journal.pone.0283887 · Cited by 7
Polański, J., Bogocz, J., & Tkocz, A. (2015) · Drug Discovery Today · doi:10.1016/j.drudis.2015.06.015 · Cited by 7
Topical Drug Innovation From 2000 Through 2014
Walter, J. R., & Xu, S. (2015) · JAMA Dermatology · doi:10.1001/jamadermatol.2015.0231 · Cited by 7
A history of drug development in four acts
Kinch, M. S., & Hoyer, D. (2015) · Drug Discovery Today · doi:10.1016/j.drudis.2015.04.003 · Cited by 7
Self-citationBarriers for Pharmaceutical Innovation With Focus in Cancer Drugs, the Case of Mexico
Dueñas‐González, A., & González‐Fierro, A. (2020) · Therapeutic Innovation & Regulatory Science · doi:10.1007/s43441-019-00062-w · Cited by 7
Medication management in Minnesota schools: The need for school nurse–pharmacist partnerships
Little, M. M., Eischens, S., Martin, M. J., Nokleby, S., Palombi, L. C., Kirk, C. V., van Risseghem, J., Wen, Y., Wozniak, J. K., Yoney, E. L., et al. (2017) · Journal of the American Pharmacists Association · doi:10.1016/j.japh.2017.10.007 · Cited by 7
Jaiswal, N., & Kumar, A. (2024) · Chinese Journal of Integrative Medicine · doi:10.1007/s11655-024-3913-3 · Cited by 6
In vitro Anti-Cancer Activity of Rosuvastatin and Ketorolac Nanoformulations against DDX3
Bheemanapally, K., Thimmaraju, M. K., Kasagoni, S., Thatikonda, P., Akula, S., Kranthi Raj, K., Kakarla, L., Gummadi, S. B., Nemani, H., & Botlagunta, M. (2017) · Journal of Young Pharmacists · doi:10.5530/jyp.2017.9.103 · Cited by 6
Sources of innovation: an assessment of intellectual property
Kinch, M. S., & Raffo, J. D. (2014) · Drug Discovery Today · doi:10.1016/j.drudis.2014.12.002 · Cited by 6
Self-citationKwa, M. C., Tegtmeyer, K., Welty, L. J., Raney, S. G., Luke, M. C., Xu, S., & Kong, B. Y. (2020) · Archives of Dermatological Research · doi:10.1007/s00403-020-02042-9 · Cited by 6
A Bayesian approach to toxicological testing
Felli, J. C., & Leishman, D. J. (2020) · Journal of Pharmacological and Toxicological Methods · doi:10.1016/j.vascn.2020.106898 · Cited by 6
Stoner, S. C., & Billings, S. (2020) · Currents in Pharmacy Teaching and Learning · doi:10.1016/j.cptl.2020.08.006 · Cited by 6
A proteomic landscape of pharmacologic perturbations for functional relevance
Liu, Z., Jiang, S., Hao, B., Xie, S., Liu, Y., Huang, Y., Xu, H., Luo, C., Huang, M., Tan, M., et al. (2023) · Journal of Pharmaceutical Analysis · doi:10.1016/j.jpha.2023.08.021 · Cited by 6
Chao, Y., Wu, C.-J., Wu, H., & Chen, W. (2019) · PLoS ONE · doi:10.1371/journal.pone.0214718 · Cited by 5
Natural experiment concept to accelerate the Re-purposing of existing therapeutics for Covid-19
Daughton, C. G. (2020) · Global Epidemiology · doi:10.1016/j.gloepi.2020.100026 · Cited by 5
Pourquoi les nouveaux médicaments sont-ils si chers ?
Galès, C. L. (2018) · médecine/sciences · doi:10.1051/medsci/20183404017 · Cited by 5
Bioactive Molecules of the Human Microbiome
Pauer, H., Glatthardt, T., Ferreira, N. V., Ferreira, R. B. R., & Antunes, L. C. M. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-815249-2.00012-9 · Cited by 5
Wallis, D. J., Du, J. K. L., Thunga, P., Elson, D. J., Truong, L., Kolluri, S. K., Tanguay, R. L., & Reif, D. M. (2022) · Frontiers in Toxicology · doi:10.3389/ftox.2022.846221 · Cited by 5
Aronson, J. K., & Green, A. R. (2019) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.14016 · Cited by 4
Paradigms for the development of transformative medicines—lessons from the EGFR story
Pao, W. J., & Nagel, Y. A. (2022) · Annals of Oncology · doi:10.1016/j.annonc.2022.02.005 · Cited by 4
Antibiotic resistance: retrospect and prospect
Aslam, B., Ahmad, M., Tariq, M. U., Muzammil, S., Siddique, A. B., Khurshid, M., Shahid, A., Rasool, M. H., Chaudhry, T. H., Amir, A., et al. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-99866-6.00008-8 · Cited by 4
2014 in review: FDA approval of new drugs
Kinch, M. S. (2015) · Drug Discovery Today · doi:10.1016/j.drudis.2015.06.004 · Cited by 4
Self-citationFrom academia to industry: a road more travelled
Pao, W. J. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx319 · Cited by 4
Eliciting improved antibacterial efficacy of host proteins in the presence of antibiotics
Jammal, J., Zaknoon, F., & Mor, A. (2017) · The FASEB Journal · doi:10.1096/fj.201700652r · Cited by 4
Kumar, S., Pandey, A. R., Singh, S. P., Swain, A., Bisen, A. C., Agrawal, S., Parwez, S., Mishra, D. P., Bhatta, R. S., Siddiqi, M. I., et al. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.117894 · Cited by 3
Sharmeen, S., Kyei, I., Poddar, S., Iftekhar, S., Sajeeb, B., Graham, L. M., Snow, D. D., & Hage, D. S. (2026) · Journal of Separation Science · doi:10.1002/jssc.70345 · Cited by 3
Catharina, L., Lima, C. R., Franca, A., Guimarães, A. C. R., Alves-Ferreira, M., Tufféry, P., Derreumaux, P., & Carels, N. (2017) · Bioinformatics and Biology Insights · doi:10.1177/1177932217712471 · Cited by 3
Chang, C.-W., Yamanaka, T., & Kano, S. (2018) · Technovation · doi:10.1016/j.technovation.2018.06.004 · Cited by 3
Shao, Z., Kyriakopoulou, L. G., & Ito, S. (2019) · Handbook of analytical separations · doi:10.1016/b978-0-444-64066-6.00014-9 · Cited by 5
Integrating pharmacogenomics into clinical trials of hearing disorders
Brutnell, T. P., Wang, X., & Bao, J. (2022) · The Journal of the Acoustical Society of America · doi:10.1121/10.0015092 · Cited by 3
Post-approval fate of pharmaceutical companies
Kinch, M. S. (2014) · Drug Discovery Today · doi:10.1016/j.drudis.2014.10.013 · Cited by 3
Self-citationEngineered OAKs Against Antibiotic Resistance and for Bacterial Detection
Mor, A. (2016) · Springer eBooks · doi:10.1007/978-3-319-32949-9_8 · Cited by 3
System Biology to Access Target Relevance in the Research and Development of Molecular Inhibitors
Catharina, L., de Menezes, M. A., & Carels, N. (2018) · Computational biology · doi:10.1007/978-3-319-74974-7_12 · Cited by 3
The role of drug metabolism in drug discovery and development : case ospemifene
Uusitalo, J. (2015) · Cited by 2
Sarikhani, A., Zadeh, S. V., Tahmasebi, S., Farahani, B. K., Nik, M. H., & Mohajerani, H. R. (2022) · Nutritional Neuroscience · doi:10.1080/1028415x.2022.2051124 · Cited by 2
Glezerman, M., Louwen, F., & Mahmood, T. (2025) · European Journal of Obstetrics & Gynecology and Reproductive Biology · doi:10.1016/j.ejogrb.2025.114720 · Cited by 2
Strategies for Tackling Drug Resistance in Tuberculosis
Maveyraud, L. (2017) · Springer eBooks · doi:10.1007/978-981-10-5187-6_7 · Cited by 2
NIH Support for FDA-Approved Medicines
Griesenauer, R. H., Moore, R., & Kinch, M. S. (2017) · Cell chemical biology · doi:10.1016/j.chembiol.2017.11.002 · Cited by 2
Self-citationKryshchyshyn‐Dylevych, A., Kaminskyy, D. V., & Lesyk, R. (2015) · Journal of organic and pharmaceutical chemistry · doi:10.24959/ophcj.15.833 · Cited by 2
Drug Repurposing Techniques in Viral Diseases
Zhang, R., Oerlemans, R., Wang, C., Zhang, L., & Groves, M. R. (2022) · IntechOpen eBooks · doi:10.5772/intechopen.101443 · Cited by 2
Silva, D. F., & Padilha, I. Q. D. M. (2022) · Arquivos de Ciências da Saúde · doi:10.17696/2318-3691.30.1.2023.172 · Cited by 2
Insight Approaches of Medicinal Plants for the Discovery of Anticancer Drugs
Pinto, D. C. G. A., Seca, A. M. L., & Silva, A. M. S. (2017) · Springer eBooks · doi:10.1007/978-981-10-8216-0_4 · Cited by 2
An Extensible Semantic Search Engine for Biomedical Publications
Kohlschein, C., Klischies, D., Paulus, A., Burgdorf, A., Meisen, T., & Kipp, M. (2018) · IEEE International Conference on e-Health Networking, Applications and Services (Healthcom) · doi:10.1109/healthcom.2018.8531123 · Cited by 2
Depth of Clinical Pharmacology in Undergraduate Medical Education
Goldstein, F. J. (2019) · Journal of Osteopathic Medicine · doi:10.7556/jaoa.2019.104 · Cited by 2
Anterior cingulate cortex dysfunction underlies anxiety-like behaviors in MT2-deficient mice
Wang, X., Zhuo, L., Wu, W. T., Cui, D., Sun, H. S., Wang, F., Luo, P., Lyu, Y., Zhai, Y., Han, J., et al. (2025) · Neuropharmacology · doi:10.1016/j.neuropharm.2025.110652 · Cited by 1
Structural Aspects of Proline Methanologues in Drug Design, Optimization, and Development
Hanessian, S., & Meanwell, N. A. (2026) · The Journal of Organic Chemistry · doi:10.1021/acs.joc.5c03173 · Cited by 1
Indemnification, Monitoring, and Competition: Evidence from R&D Contracts
Guo, D., Hua, X., & Jiang, K. (2022) · American Law and Economics Review · doi:10.1093/aler/ahac004 · Cited by 1
Evaluation of Drug-related Emergency Department Admissions in a Tertiary Care Hospital
Shafiq, N., Sharma, N., Bhalla, A., Kumar, G., Harish, C., & Malhotra, S. (2020) · Journal of Postgraduate Medicine Education and Research · doi:10.5005/jp-journals-10028-1356 · Cited by 1
Barriers for Pharmaceutical Innovation With Focus in Cancer Drugs, the Case of Mexico
Dueñas‐González, A., & González‐Fierro, A. (2019) · Therapeutic Innovation & Regulatory Science · doi:10.1177/2168479019839015 · Cited by 1
Saxena, R., Shrinet, K., Saxena, R., Panwar, Y. S., & Jain, M. (2022) · Asian Journal of Chemistry · doi:10.14233/ajchem.2022.23899 · Cited by 1
Toward an ethical framework for geroscience?
Faragher, R. (2023) · Advances in biogerontology · doi:10.1016/bs.abger.2023.06.001 · Cited by 1
Pharmaceutical Industry: Good and Bad
Cherecheș, M. C. (2023) · Springer eBooks · doi:10.1007/978-3-031-45774-6_9 · Cited by 1
Introduction to Drug-Drug Interactions
Pai, M. P., Kiser, J. J., Gubbins, P. O., & Rodvold, K. A. (2018) · Springer eBooks · doi:10.1007/978-3-319-72422-5_1 · Cited by 1
The Strategy Research of Pharmaceutical Enterprises-Taking Pfizer as an Example
Yang, S. (2023) · Advances in economics, business and management research/Advances in Economics, Business and Management Research · doi:10.2991/978-94-6463-098-5_28 · Cited by 1
Occupational Toxicology in the Pharmaceutical Industry
Dolan, D. G., Bercu, J. P., Graham, J. C., & Barle, E. L. (2023) · Patty's Toxicology · doi:10.1002/0471125474.tox112.pub3 · Cited by 1
Access to Medicines : Common problems, common solutions?
Stephens, P. N. (2015) · Utrecht University Repository (Utrecht University)
Sources of Biopharmaceutical Innovation: An Assessment of Intellectual PropertyPreprint
Kinch, M. S., & Raffo, J. D. (2023) · SSRN Electronic Journal · doi:10.2139/ssrn.4434849
Self-citationdos Santos, R. N. (2016) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.76.2016.tde-02022016-163931
Pharmacoeconomics as a Response to Market Failure: An International Perspective
Lopert, R. (2016) · CRC Press eBooks · doi:10.1201/b19633-18
Financing Pharmaceutical Innovation
Sivagrakau, S. (2016) · Wiley eBooks · doi:10.1002/9783527693405.ch5
Morrison, J. S., & Hageman, M. J. (2017) · AAPS advances in the pharmaceutical sciences series · doi:10.1007/978-3-319-50042-3_14
Green Process Chemistry in the Pharmaceutical Industry: Case Studies Update (2012–2016)
Fortunak, J., Zhang, J., Nytko, F. E., & Ellison, T. (2018) · Wiley eBooks · doi:10.1002/9781119288152.ch23
Pitta, F. D. (2018) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.59.2018.tde-19122017-230524
Biomedical Importance of Marine Peptides/Toxins
Ramachandran, S., & Rajagopal, S. (2019) · Springer eBooks · doi:10.1007/978-981-13-7844-7_1
Fumagalli, F. (2019) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.60.2019.tde-27052019-111337
İlaçların Neden Olduğu Tat ve Koku Alma Bozuklukları
BAŞARAN, M. M., & Bacanli, M. G. (2020) · Turkish Journal of Family Medicine & Primary Care · doi:10.21763/tjfmpc.616997
Experiences in Academic and Industry Partnerships – Forging a Path to Translational Drug Discovery
Dolle, R. E., Barrault, D. V., Carragher, N. O., Andrews, P. D., Ebner, D. V., Hopkins, A., Kojima, H., Frye, S. V., Edwards, A., Dosa, P. I., et al. (2021) · Wiley eBooks · doi:10.1002/0471266949.bmc292
Self-citationIntellectual Property for Biotechnology and Pharmaceutical Products
Kelley, J. J., Stemerick, D., Norton, V., Welch, L., Gregory, J. K., Cox, G., Rudolph, J., Castetter, A. M., & Myers, M. R. (2021) · Burger's Medicinal Chemistry and Drug Discovery · doi:10.1002/0471266949.bmc040.pub3
NATURAL PRODUCTS: THE LEADING INDUSTRY AS PHARMACEUTICAL DRUGS
Panwar, K., Kumar, P., Kulkarni, M. P., Kumar, R., & Singh, G. (2020) · PLANT ARCHIVES · doi:10.51470/plantarchives.2021.v21.s1.385
Microbial volatiles as new frontiers in antibiotic research
Mangrolia, U., & Osborne, W. J. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-824523-1.00016-x
de Wit, H. (2016) · Research Publications (Maastricht University) · doi:10.26481/dis.20161130hw
Al-Marie, T. (2021) · Future of business and finance · doi:10.1007/978-3-030-65896-0_18
Durán–Álvarez, J. C., & Jiménez, B. E. (2021) · Elsevier eBooks · doi:10.1016/b978-0-08-102971-8.00022-6
Structure and Dynamics of the Pharmaceutical Industry
Lipowski, E. E. (2016) · CRC Press eBooks · doi:10.1201/b19633-14
Burgers, L. D. (2022) · Publication Server of Goethe University Frankfurt am Main (Goethe University Frankfurt) · doi:10.21248/gups.68198
Davis, J. S. (2022) · Physician Assistant Clinics · doi:10.1016/j.cpha.2022.10.004
Toxinology of Venomous Marine Worms; A Review
Mohebbi, G., Maryamabadi, A., & Nabipour, I. (2020) · Iranian South Medical Journal · doi:10.52547/ismj.23.4.371
Metadata
- Authors
- Kinch, M. S., Haynesworth, A., Kinch, S. L., & Hoyer, D.
- Affiliations
- Yale University (US)
- Corresponding author
- Kinch, Michael S.
- Venue
- Drug Discovery Today
- Publisher
- Elsevier BV
- Published
- 2014-08
- Volume
- 19
- Issue
- 8
- Pages
- 1033-1039
- ISSN
- 1359-6446 (ISSN-L)
- OpenAlex
- W2046088696
- Cited by
- 210
- References
- 7
- Citations by year
- 2026: 4 · 2025: 6 · 2024: 5 · 2023: 17 · 2022: 12 · 2021: 15 · 2020: 22 · 2019: 24 · 2018: 25 · 2017: 28 · 2016: 22 · 2015: 22 · 2014: 8
- FWCI
- 66.12
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Drug Discovery Today (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Pharmaceutical Economics and Policy
- Health Sciences › Nursing › Issues, ethics and legal aspects › Pharmaceutical industry and healthcare
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Firm Innovation and Growth
- Keywords
- new chemical entities, FDA-approved drugs, drug development trends, pharmaceutical industry consolidation, drug discovery, pharmaceutical companies, marketing organization, drug approval rates
- MeSH terms
- Drug Industry, Time Factors, United States, United States Food and Drug Administration, Drug Approval, Drug Discovery
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
